Remifentanil TCI appears to provide better conditions for AFOI when compared with propofol TCI. The disadvantage of remifentanil in this setting may be a higher incidence of recall.

No abstract

No abstract

4.6% -26.2% vs. 3.1% -12.5%) was better with combination therapy vs. control group therapies. In two studies, patients on vandetinib and docetaxel combination therapy showed a significant improvement (p< 0•0001) in PFS and overall response rate versus those randomly assigned to receive docetaxel only. Results of metaanalysis demonstrate that combined targeted therapy has better OS (WMD: 1.23 [95% CI: 0.06, 2.41], p = 0.04), PFS (WMD: 1.07 [95% CI: 0.7, 1.45], p < 0.00001) and ORR (OR: 1.85 [95% CI: 1.49, 2.31], p < 0.00001). The AE profile (gastrointestinal, vascular, infectious and blood disorders) was better in the control group therapies. ConClusions: Survival benefit and response rate with combined inhibition therapy against EGFR and VEGF was better than the VEGF or EGFR alone inhibition. Combination therapy was associated with increased toxicity resulting in low compliance and dose reduction or discontinuation.